

Kardiovaskuläre Rehabilitation bei Patienten mit koronarer Herzkrankheit

A. Salzwedel, R. Reibis, H. Völler

Literatur:

1. Herzstiftung D. Deutscher Herzbericht 2019 (09.11.2020). Im Internet: <https://www.herzstiftung.de/e-paper/#0>; Stand: 16.12.2020
2. Deutsche Herzstiftung. 29. Deutscher Herzbericht 2017. Sektorenübergreifende Versorgungsanalyse zur Kardiologie, Herzchirurgie und Kinderherzmedizin in Deutschland; 2017
3. Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislaufkrankungen (DGPR) e. V., Österreichische Kardiologische Gesellschaft (ÖKG), Arbeitsgruppe Prävention, Rehabilitation und Sportkardiologie, Swiss Working Group for Cardiovascular Prevention, Rehabilitation and Sports Cardiology. S3–Leitlinie zur kardiologischen Rehabilitation (LL-KardReha) im deutschsprachigen Raum Europas, Deutschland, Österreich, Schweiz (D-A-CH). Gesamtversion-Langfassung, 2020 AWMF Registernummer: 133/001. Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/133-001l_S3-Kardiologische-Rehabilitation-in-D-A-CH_2020-01.pdf; Stand: 15.06.2021
4. Pedretti RFE et al. Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients: a consensus document from the European Association of Preventive Cardiology (EAPC; Secondary prevention and rehabilitation section) and European Heart Rhythm Association (EHRA). *Eur J Prev Cardiol* 2021; Jan 26: zwaa121
5. Karoff M et al. Cardiac rehabilitation in Germany. *Eur J Cardiovasc Prev Rehabil* 2007; 14: 18–27
6. Rauch B et al. Short-term comprehensive cardiac rehabilitation after AMI is associated with reduced 1-year mortality: results from the OMEGA study. *Eur J Prev Cardiol* 2014; 21: 1060–1069
7. Ambrosetti M et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2021; 28: 460–495
8. Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD). GBD Compare | IHME Viz Hub. Im Internet: <https://vizhub.healthdata.org/gbd-compare/>; Stand: 15.06.2021
9. Seekatz B et al. Entwicklung und kurzfristige Effektivität eines standardisierten Schulungsprogramms für die Rehabilitation bei koronarer Herzkrankheit. *Rehabilitation (Stuttg)* 2013; 52: 344–351
10. Deutsche Rentenversicherung Bund. Reha-Therapiestandards Koronare Herzkrankheit für die medizinische Rehabilitation der Rentenversicherung
11. Vogel B et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. *The Lancet* 2021; 397: 2385–2438
12. Chou AY et al. The First Dedicated Cardiac Rehabilitation Program for Patients With Spontaneous Coronary Artery Dissection: Description and Initial Results. *Can J Cardiol* 2016; 32: 554–560
13. Baggish AL et al. Sports Cardiology: Core Curriculum for Providing Cardiovascular Care to Competitive Athletes and Highly Active People. *J Am Coll Cardiol* 2017; 70: 1902–1918
14. Deutsches Zentrum für Altersfragen. Deutscher Alterssurvey 2014: Zentrale Befunde. Berlin; 2016
15. Eichler S et al. Octogenarians in interventional cardiology: Feasibility and safety of functional and nutritional assessments for a new patient group in cardiac rehabilitation. *Eur J Prev Cardiol* 2020; 27: 2345–2347
16. Rauch B et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies - The Cardiac Rehabilitation Outcome Study (CROS). *Eur J Prev Cardiol* 2016; 23: 1914–1939
17. Salzwedel A et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study (CROS-II). *Eur J Prev Cardiol* 2020; 27: 1756–1774
18. Anderson L et al. Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis. *J Am Coll Cardiol* 2016; 67: 1–12

19. Lamberti M et al. Work-related outcome after acute coronary syndrome: Implications of complex cardiac rehabilitation in occupational medicine. *Int J Occup Med Environ Health* 2016; 29: 649–657
20. Worcester MU et al. Resumption of work after acute coronary syndrome or coronary artery bypass graft surgery. *Heart Lung Circ* 2014; 23: 444–453
21. Simchen E et al. Is participation in cardiac rehabilitation programs associated with better quality of life and return to work after coronary artery bypass operations? The Israeli CABG Study. *Isr Med Assoc J* 2001; 3: 399–403
22. Salzwedel A et al. Patient-reported outcomes predict return to work and health-related quality of life six months after cardiac rehabilitation: Results from a German multi-centre registry (OutCaRe). *PLOS ONE* 2020; 15: e0232752

Besonderheiten der kardiologischen Rehabilitation bei selteneren Indikationen

J.-P. Schmid

Literatur:

1. Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-und Kreislauferkrankungen (DGPR) et al. S3-Leitlinie zur kardiologischen Rehabilitation (LL-KardReha) im deutschsprachigen Raum Europas Deutschland, Österreich, Schweiz (D-A-CH). Gesamtversion 2020 AWMF-Registernummer: 133-001. Version 1.1, 10.12.2020 https://www.awmf.org/uploads/tx_szleitlinien/133-001k_S3-Kardiologische-Rehabilitation-in-D-A-CH_2020-12.pdf
2. Delsart P et al. Post aortic dissection: Gap between activity recommendation and real life patients aerobic capacities. *Int J Cardiol* 2016; 219: 271–6
3. Eggebrecht H et al. Resistant hypertension in patients with chronic aortic dissection. *J Hum Hypertens* 2005; 19: 227–31
4. Chaddha A et al. Exercise and Physical Activity for the Post-Aortic Dissection Patient: The Clinician's Conundrum. *Clin Cardiol* 2015; 38: 647–51
5. Doimo S et al. Impact of ambulatory cardiac rehabilitation on cardiovascular outcomes: a long-term follow-up study. *Eur Heart J* 2019; 40: 678–85
6. Erbel R et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014; 35: 2873–926
7. Lakoski SG et al. The safety and efficacy of early-initiation exercise training after acute venous thromboembolism: a randomized clinical trial. *J Thromb Haemost* 2015; 13: 1238–44
8. Noack F et al. Feasibility and safety of rehabilitation after venous thromboembolism. *Vasc Health Risk Manag* 2015; 11: 397–401
9. Kahn SR et al. Physical activity in patients with deep venous thrombosis: a systematic review. *Thromb Res* 2008; 122: 763–73
10. Hach-Wunderle V et al. Interdisziplinäre S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Hogrefe. 2016
11. Grunig E et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. *Eur Respir J* 2012; 40: 84–92
12. Grunig E et al. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. *Eur Respir J* 2019; 53
13. Maron BJ et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. *Circulation* 2015; 132: e273–80

14. Piori SG et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2015; 36: 2793–867

Kardiovaskuläre Rehabilitation bei Patienten mit peripherer arterieller Verschlusskrankheit (PAVK)

G. Dörr, R. Westphal

Literatur:

1. Falk J et al. Rehabilitation von Menschen mit einer peripheren arteriellen Verschlusskrankheit im Kontext aktueller Leitlinien. Eine Analyse auf Basis von Routinedaten. *Rehabilitation* 2019; 58: 225–233
2. Bauersachs R et al. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. *Cardiovasc Ther* 2019; 2019: 8295054
3. Criqui MHL et al. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med* 1992; 326: 381–386
4. Kalbaugh CA et al. Frequency of Care and Mortality Following an Incident Diagnosis of Peripheral Artery Disease in the Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study. *J Am Heart Assoc* 2018; 7: e007332
5. Armstrong EJ et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. *J Am Heart Assoc* 2014; 3: 1–11
6. Baviera M et al. Peripheral arterial disease: Changes in clinical outcomes and therapeutic strategies in two cohorts, from 2002 to 2008 and from 2008 to 2014. A population-based study. *Eur J Prev Cardiol* 2018; 25: 1735–1743
7. Arya S et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. *Circulation* 2018; 137: 1435–1446
8. Hussain MA et al. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. *JAMA Surg* 2016; 151: 742–750
9. Hamburg NM & Creager MA. Pathophysiology of Intermittent Claudication in Peripheral Artery Disease. *Circ J* 2017; 81: 281–289
10. Aboyans V et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J* 2018; 39: 763–816
11. Lane R et al. Exercise for intermittent claudication. *Cochrane Database Syst Rev* 2017; 12: CD000990
12. McDermott MM Exercise Rehabilitation for Peripheral Artery Disease: A Review. *J Cardiopulm Rehabil Prev* 2018; 38: 63–69
13. Lawall H et al. Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin, (AWMF) AdWMF. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit 2015 [AWMF-Register Nr. 065/03 Entwicklungsstufe 3].

14. S3-Leitlinie zur kardiologischen Rehabilitation (LL-KardReha) im deutschsprachigen Raum Europas, Deutschland, Österreich, Schweiz (D-A-CH). Gesamtversion (Version 1.1) vom 10.12.2020; AWMF Registernummer: 133/001; www.awmf.org
15. Cavalcante BR et al. Are the barriers for physical activity practice equal for all peripheral artery disease patients? *Arch Phys Med Rehabil* 2015; 96: 248–252
16. Milani RV & Lavie CJ. The role of exercise training in peripheral arterial disease. *Vasc Med* 2007; 12: 351–358
17. Hiatt WR et al. Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. *Circ Res* 2015; 116(9): 1527–39
18. Baitsch G & Layher T. Hrsg. Sozialmedizinische Beurteilung für die gesetzliche Rentenversicherung. Gefäßkrankheiten. Springer, Berlin Heidelberg; 2003. S. 329–343
19. Stauber S et al. Psychosocial outcome in cardiovascular rehabilitation of peripheral artery disease and coronary artery disease patients. *Vasc Med* 2013; 18: 257–262
20. Lyu X et al. Intensive walking exercise for lower extremity peripheral arterial disease: A systematic review and meta-analysis. *J Diabetes*. 2016; 8(3): 363–77
21. Parmenter BJ et al. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. *Vasc Med*. 2015; 20(1): 30-40
22. Parmenter BJ et al. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. *Sports Med* 2015; 45: 231–244
23. Pandey A et al. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv*. 2017; 10(7): 712–24
24. Meneses AL et al. Combined Lower Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial Disease: A Systematic Review of Randomised Controlled Trials. *Sports medicine (Auckland, NZ)*. 2017; 47(5): 987–1002
25. Batra A et al. S3-Leitlinie Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) 2015 [AWMF-Register Nr. 076-06]. Available from: https://www.awmf.org/uploads/tx_szleitlinien/076-006l_S3_Tabak_2015-02.pdf
26. Rejeski WJ et al. A group-mediated, home-based physical activity intervention for patients with peripheral artery disease: effects on social and psychological function. *J Transl Med*. 2014; 12: 29
27. Slysz, JT et al. Effects of supervised exercise therapy on blood pressure and heart rate during exercise, and associations with improved walking performance in peripheral artery disease: Results of a randomized clinical trial. *J vasculat* 2021; S0741 5214(21): 00849-1

Herzinsuffizient mit reduzierter Ejektionsfraktion (HFrEF) – Therapie im Wandel

V. Fabiunke-Dörr, C. Birner

Literatur:

1. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European heart journal*. 2016; 37: 2129–200
2. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz – Langfassung, 3. Auflage. Version 2. 2019
3. McMurray JJV et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J med* 2014; 371: 993–1004
4. Januzzi JL et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. *JAMA*. 2019; 322: 1085–95
5. Velazquez EJ et al. Angiotensin-Nepriylsin Inhibition in Acute Decompensated Heart Failure. *N Engl J med* 2019; 380: 539–48
6. Maddox TM et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2021; 77: 772–810
7. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *The N Engl J med* 2015; 373: 2117–28
8. McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J med* 2019; 381: 1995–2008
9. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J med* 2020; 383: 1413–24
10. Zannad F et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 2020; 396: 819–29
11. Vaduganathan M et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials. *Lancet* 2020; 396: 121–28
12. Ashman DF et al. Isolation of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate from rat urine. *Biochemical and Biophysical Research Communications*. 1963; 11: 330–34
13. Bork NI & Nikolaev VO. cGMP Signaling in the Cardiovascular System-The Role of Compartmentation and Its Live Cell Imaging. *International journal of molecular sciences*. 2018; 19
14. Follmann M et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. *Journal of medicinal chemistry*. 2017; 60: 5146–61
15. Gheorghiade M et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*. 2015; 314: 2251–62
16. Armstrong PW et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J med* 2020; 382: 1883–93
17. Ezekowitz JA et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. *JACC. Heart failure*. 2020; 8: 931–39
18. Kadish A et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J med* 2004; 350: 2151–58
19. Køber L et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. *N Engl J med* 2016; 375: 1221–30
20. Baumgartner H et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur heart J* 2017; 38: 2739–91

21. Obadia J-F et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. *N Engl J med* 2018; 379: 2297–306
22. Stone GW et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. *N Engl J med* 2018; 379: 2307–18
23. Pibarot P et al. MITRA-FR vs. COAPT: Lessons from two trials with diametrically opposed results. *Eur heart J Cardiovasc Imaging* 2019; 20: 620–24
24. Grayburn PA et al. Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. *JACC. Cardiovasc imaging* 2019; 12: 353–62
25. Otto CM et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2021; 143: e72-e227
26. Marrouche NF et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. *N Engl J med* 2018; 378: 417–27
27. Noseworthy PA et al. Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. *Heart rhythm* 2020; 17: 1057–65
28. Hindricks G et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur heart J* 2021; 42: 373–498